רמיקד

Pays: Israël

Langue: hébreu

Source: Ministry of Health

Ingrédients actifs:

INFLIXIMAB 100 MG/VIAL

Disponible depuis:

J-C HEALTH CARE LTD

Code ATC:

L04AA12

forme pharmaceutique:

POWDER FOR CONCENTRATE FOR INFUSION

Mode d'administration:

I.V

Fabriqué par:

JANSSEN BIOLOGICS, BV, THE NETHERLAND

Groupe thérapeutique:

INFLIXIMAB

indications thérapeutiques:

- Adult :Crohn's disease: Treatment of severe active Crohn's disease in patients who have not responded despite of a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant. Treatment of fistulising Crohn's disease in patients who have not responded despite of a full and adequate course of therapy with conventional treatment. -Paediatric Crohn's disease: Remicade is indicated for: Treatment of severe active crohn's disease in paediatric patients aged 6 to 17 years who have not responded to conventional therapy including a corticosteroid an immunomodulator and primary nutrition therapy or who are intolerant to or have contraindications for such therapies. Remicade has been studied only in combination with conventional immunosuppressive therapy -Ankylosing spondylitis: Remicade is indicated for: treatment of ankylosing spondylitis in patients who have severe axial symptoms elevated serological markers of inflammatory activity and who have responded inadequately to conventional ther

Date de l'autorisation:

2010-01-01